• Je něco špatně v tomto záznamu ?

Změnila dlouho očekávaná léčba eprodisatem sodným prognózu nemocných se sekundární amyloidózou?
[Eprodisate for the treatment of renal disease in AA amyloidosis]

Dember LM, Hawkins PN, Hazenberg BPC, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W,

. 2007 ; 5 (4) : 59.

Jazyk čeština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07505871

Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils. Amyloid deposition in the kidney causes progressive deterioration in renal function. Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of eprodisate in patients with AA amyloidosis and kidney involvement. We randomly assigned 183 patients from 27 centers to receive eprodisate or placebo for 24 months. The primary composite end point was an assessment of renal function or death. Disease was classified as worsened if any one of the following occurred: doubling of the serum creatinine level, reduction in creatinine clearance by 50% or more, progression to end-stage renal disease, or death. RESULTS: At 24 months, disease was worsened in 24 of 89 patients who received eprodisate (27%) and 38 of 94 patients given placebo (40%, P=0.06); the hazard ratio for worsening disease with eprodisate treatment was 0.58 (95% confidence interval, 0.37 to 0.93; P=0.02). The mean rates of decline in creatinine clearance were 10.9 and 15.6 ml per minute per 1.73 m(2) of body-surface area per year in the eprodisate and the placebo groups, respectively (P=0.02). The drug had no significant effect on progression to end-stage renal disease (hazard ratio, 0.54; P=0.20) or risk of death (hazard ratio, 0.95; P=0.94). The incidence of adverse events was similar in the two groups. CONCLUSIONS: Eprodisate slows the decline of renal function in AA amyloidosis. (ClinicalTrials.gov number, NCT00035334.) Copyright 2007 Massachusetts Medical Society.

Eprodisate for the treatment of renal disease in AA amyloidosis

Recenze v:

Komentář [k článku Změnila dlouho očekávaná léčba eprodisatem sodným prognózu nemocných se sekundární amyloidózou?].

000      
05124naa 2200685 a 4500
001      
bmc07505871
003      
CZ-PrNML
005      
20111210122430.0
008      
080625s2007 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Dember, L. M.
245    10
$a Změnila dlouho očekávaná léčba eprodisatem sodným prognózu nemocných se sekundární amyloidózou? / $c Dember LM, Hawkins PN, Hazenberg BPC, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W,
246    11
$a Eprodisate for the treatment of renal disease in AA amyloidosis
314    __
$a Boston University School of Medicine, Boston
520    9_
$a Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils. Amyloid deposition in the kidney causes progressive deterioration in renal function. Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of eprodisate in patients with AA amyloidosis and kidney involvement. We randomly assigned 183 patients from 27 centers to receive eprodisate or placebo for 24 months. The primary composite end point was an assessment of renal function or death. Disease was classified as worsened if any one of the following occurred: doubling of the serum creatinine level, reduction in creatinine clearance by 50% or more, progression to end-stage renal disease, or death. RESULTS: At 24 months, disease was worsened in 24 of 89 patients who received eprodisate (27%) and 38 of 94 patients given placebo (40%, P=0.06); the hazard ratio for worsening disease with eprodisate treatment was 0.58 (95% confidence interval, 0.37 to 0.93; P=0.02). The mean rates of decline in creatinine clearance were 10.9 and 15.6 ml per minute per 1.73 m(2) of body-surface area per year in the eprodisate and the placebo groups, respectively (P=0.02). The drug had no significant effect on progression to end-stage renal disease (hazard ratio, 0.54; P=0.20) or risk of death (hazard ratio, 0.95; P=0.94). The incidence of adverse events was similar in the two groups. CONCLUSIONS: Eprodisate slows the decline of renal function in AA amyloidosis. (ClinicalTrials.gov number, NCT00035334.) Copyright 2007 Massachusetts Medical Society.
650    _2
$a amyloidóza $x etiologie $x farmakoterapie $x mortalita $7 D000686
650    _2
$a revmatoidní artritida $x komplikace $7 D001172
650    _2
$a kreatin $x krev $7 D003401
650    _2
$a progrese nemoci $7 D018450
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a familiární středomořská horečka $x komplikace $7 D010505
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glykosaminoglykany $x antagonisté a inhibitory $7 D006025
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a nemoci ledvin $x etiologie $x farmakoterapie $x mortalita $7 D007674
650    _2
$a chronické selhání ledvin $x prevence a kontrola $7 D007676
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a propan $x analogy a deriváty $x škodlivé účinky $x terapeutické užití $7 D011407
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a proteinurie $7 D011507
650    _2
$a sérový amyloid A $x škodlivé účinky $7 D000685
650    _2
$a kyseliny sulfonové $x škodlivé účinky $x terapeutické užití $7 D013451
700    1_
$a Hawkins, P. N.
700    1_
$a Hazenberg, B. P. C.
700    1_
$a Gorevic, P. D.
700    1_
$a Merlini, G.
700    1_
$a Butrimiene, I.
700    1_
$a Livneh, A.
700    1_
$a Lesnyak, O.
700    1_
$a Puechal, X.
700    1_
$a Lachmann, H. J.
700    1_
$a Obici, L.
700    1_
$a Balshaw, R.
700    1_
$a Garceau, D.
700    1_
$a Hauck, W.
773    0_
$w MED00012709 $t Postgraduální nefrologie $g Roč. 5, č. 4 (2007), s. 59 $x 1214-178X
787    18
$w bmc07505872 $i Recenze v: $t Komentář [k článku Změnila dlouho očekávaná léčba eprodisatem sodným prognózu nemocných se sekundární amyloidózou?]
856    41
$u https://www.postgradualninefrologie.cz/download/format/pdf/id/325/ $y plný text volně přístupný
910    __
$a ABA008 $b B 2318 $c 893 $y 1
990    __
$a 20080624122623 $b ABA008
991    __
$a 20080805102521 $b ABA008
999    __
$a ok $b bmc $g 621493 $s 473926
BAS    __
$a 3
BMC    __
$a 2007 $b 5 $c 4 $d 59 $i 1214-178X $m Postgraduální nefrologie $x MED00012709
LZP    __
$a 2008-6/mkmv

Najít záznam

Citační ukazatele

Možnosti archivace